Literature DB >> 23744591

Parathyroidectomy eliminates arrhythmic risk in primary hyperparathyroidism, as evaluated by exercise test.

Jessica Pepe1, Mario Curione, Sergio Morelli, Marisa Varrenti, Camillo Cammarota, Mirella Cilli, Sara Piemonte, Cristiana Cipriani, Claudio Savoriti, Orlando Raimo, Federica De Lucia, Luciano Colangelo, Carolina Clementelli, Elisabetta Romagnoli, Salvatore Minisola.   

Abstract

OBJECTIVE: To investigate whether parathyroidectomy (PTx) reverses risk factors for arrhythmias related to the QT dynamic changes evaluated during bicycle ergometry exercise test (ET).
METHODS: Twenty-four postmenopausal women with primary hyperparathyroidism (PHPT) (mean age 60.08.4 years) and 30 sex- and age-matched controls underwent ET, echocardiography, and biochemical evaluation. The following stages were considered during ET: rest, peak exercise, and recovery. The patients were randomized to two groups: 12 underwent PTx (group A) and 12 were followed-up conservatively (group B). After 6 months, the patients were studied again.
RESULTS: Groups A and B showed no differences in mean baseline biochemical values, echocardiographic parameters, and QTC interval. PHPT patients showed an increased occurrence of ventricular premature beats (VPBS) during ET compared with controls (37.0 vs 6.6%, P=0.03). Serum calcium level was a predictor of VPBS (P=0.05). Mean value of QTC was in the normal range at baseline (Group A: 401±16.9; group B: 402.25±13.5 ms) but significantly lower than controls (417.8±25.1 ms, P<0.01). A negative correlation was found between QTc and calcium values (P=0.03). Physiological reduction of QTc interval from rest to peak exercise was not observed in PHPT patients before surgery. After PTx, group A had a significant reduction in VPBs compared with baseline (at baseline, 5 of 12 vs none of 12 patients after PTx, P=0.03) and a restored normal QT adaptation during ET. Group B showed no significant changes after a 6-month period.
CONCLUSIONS: PTx reduces the occurrence of VPBs and restored the QTc adaptation during ET.

Entities:  

Mesh:

Year:  2013        PMID: 23744591     DOI: 10.1530/EJE-13-0293

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  6 in total

1.  Racial Differences in Association of Serum Calcium with Mortality and Incident Cardio- and Cerebrovascular Events.

Authors:  Jun Ling Lu; Miklos Z Molnar; Jennie Z Ma; Lekha K George; Keiichi Sumida; Kamyar Kalantar-Zadeh; Csaba P Kovesdy
Journal:  J Clin Endocrinol Metab       Date:  2016-09-15       Impact factor: 5.958

2.  Emerging data on cardiovascular risk in primary hyperparathyroidism.

Authors:  Jessica Pepe; Sara Piemonte; Cristiana Cipriani; Mirella Cilli; Salvatore Minisola
Journal:  Endocrine       Date:  2014-09-10       Impact factor: 3.633

3.  Parathyroid hormone is related to QT interval independent of serum calcium in patients with coronary artery disease.

Authors:  Nicholas O Palmeri; Karina W Davidson; William Whang; Ian M Kronish; Donald Edmondson; Marcella D Walker
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-09-26       Impact factor: 1.468

Review 4.  Effect of Parathyroidectomy Upon Left Ventricular Mass in Primary Hyperparathyroidism: A Meta-Analysis.

Authors:  Donald J McMahon; Angela Carrelli; Nick Palmeri; Chiyuan Zhang; Marco DiTullio; Shonni J Silverberg; Marcella D Walker
Journal:  J Clin Endocrinol Metab       Date:  2015-10-07       Impact factor: 5.958

5.  Minimally invasive parathyroidectomy guided by intraoperative parathyroid hormone monitoring (IOPTH) and preoperative imaging versus bilateral neck exploration for primary hyperparathyroidism in adults.

Authors:  Hala Ahmadieh; Omar Kreidieh; Elie A Akl; Ghada El-Hajj Fuleihan
Journal:  Cochrane Database Syst Rev       Date:  2020-10-21

6.  Primary hyperparathyroidism associated with acquired long QT interval and ventricular tachycardia.

Authors:  Emir Muzurović; Sanja Medenica; Milovan Kalezić; Siniša Pavlović
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2021-08-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.